Rohana Thakur News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
CHARLESTON, S.C., March 10, 2021 /PRNewswire/  GlycoPath Inc., the developer of advanced bioanalytical assays based on its proprietary GlycoTyper
TM immunoaffinity technology, announced the closing of its seed investment round with Bruker Corporation (Nasdaq: BRKR) as a new minority investor. Financial details were not disclosed.
The proprietary GlycoTyper
TM glycan profiling technology captures diagnostic glycoproteins from blood using multiplexed antibody slide arrays, followed by direct analysis of the glycans present on each glycoprotein by MALDI-TOF mass spectrometry. Presently, the GlycoTyper
TM technology is for research use only.
The initial pathology target for GlycoTyper
TM, hepatic fibrosis, is currently one of the fastest growing diseases in the US by annual case numbers, and may affect over 100 million people in the US and 1.5 billion individuals worldwide. In addition to providing initial patie ....

Bruker Daltonics , Rohana Thakur , Richard Drake , Foundation For Research Development , University Of South Carolina , Glycopath Inc , Bruker Corporation Nasdaq , Bruker Corporation , Chief Executive Officer , Peggi Angel , Chief Scientific Officer , Executive Vice President , Life Science Mass Spectrometry , Medical University , South Carolina , ரோஹனா தாகூர் , ரிச்சர்ட் டிரேக் , அடித்தளம் க்கு ஆராய்ச்சி வளர்ச்சி , பல்கலைக்கழகம் ஆஃப் தெற்கு கரோலினா , ப்ரூக்கர் நிறுவனம் நாஸ்டாக் , ப்ரூக்கர் நிறுவனம் , தலைமை நிர்வாகி அதிகாரி , தலைமை அறிவியல் அதிகாரி , நிர்வாகி துணை ப்ரெஸிடெஂட் , வாழ்க்கை அறிவியல் நிறை ஸ்பெக்ட்ரோமெட்ரி , மருத்துவ பல்கலைக்கழகம் ,